WH0913LAB Issued 05/20 No Previous Edition



COVID-19 Antibody Testing Form

Wayne HealthCare • 835 Sweitzer Street • Greenville, Ohio 45331

Name (PLEASE PRINT):	Sex: □ Female □ Male
Name (PLEASE PRINT): LAST FIRST	MIDDLE INITIAL
Date of Birth://	R OR HAVE GUARDIAN PRESENT TO PARTICIPATE)
Address:	Home Phone:
	Cell Phone:
Email Address (REQUIRED FOR PATIENT TEST RESULT PORTAL ACCESS):	
Emergency Contact and Telephone Number:	
I hereby grant permission to Wayne HealthCare Laboratory (the "Lab") to direction, which may include obtaining specimens of blood by venipuncturesults and mail them to me at the above address. I agree to pay for the te	are or finger stick. I authorize the Lab to obtain these screening
I understand that the testing has not been ordered by a physician and is be treatment purposes. Because the tests are not ordered by a physician, insurance Lab will not submit the tests to any insurance company for reimburse	rance coverage is not available, including Medicare or Medicaid
I further understand that the test results will not be forwarded to any medi It is my responsibility to share the test results with my physician at my sol information, treatment or services from a doctor or other health care provi	le option. I, alone, am responsible for obtaining medical
I HEREBY CERTIFY THAT I HAVE READ THE ABOVE ACKNOWN ASK QUESTIONS ABOUT ITS CONTENTS. BY SIGNING BELOW, LABORATORY TESTING UNDER THE CONDITIONS SET FORTH I	LEDGEMENT AND HAVE HAD AN OPPORTUNITY TO I CONSENT TO UNDERGO THE SELF-DIRECTED
PANEL PRICE  ☐ COVID-19 Antibody Testing \$65.00	
* Fasting Required. Do not eat or drink anything, except water, for 8-12 hours primedications.	rior to blood collection. Consult your physician before stopping any
TOTAL DUE: \$ PAID: Cash: \$ Check #:	Credit Card: Rec'd By:
Collection Date: Collection Time: Phleb Initial	s:
The clarity COVID-19 IgG/IgM Antibody Test is being marketed in accorrecent guidance, titled "Policy for Diagnostic Tests for Coronavirus Disea issued on March 16, 2020. The FDA issued this guidance to help accelera diagnostic tests developed by laboratories and commercial manufacturers  • This test has not been reviewed by the FDA;	use-2019 during the Public Health Emergency," which was atte the availability of novel coronavirus (COVID-19)
<ul> <li>Negative results do not rule out SARS-CoV-2 infection, particular Follow-up testing with a molecular diagnostic should be considered.</li> <li>Results from antibody testing should not be used as the sole basis infection status;</li> <li>Positive results may be due to past or present infection with non-HKU1, NL63, or 229E.</li> </ul>	arly in those who have been in contact with the virus. red to rule out infection in these individuals; s to diagnose or exclude SARS-CoV-2 infection or to inform
<ul> <li>Follow-up testing with a molecular diagnostic should be considered.</li> <li>Results from antibody testing should not be used as the sole basis infection status;</li> <li>Positive results may be due to past or present infection with non-</li> </ul>	arly in those who have been in contact with the virus. red to rule out infection in these individuals; s to diagnose or exclude SARS-CoV-2 infection or to inform SARS-CoV-2 coronavirus strains, such as coronavirus
<ul> <li>Follow-up testing with a molecular diagnostic should be considered.</li> <li>Results from antibody testing should not be used as the sole basis infection status;</li> <li>Positive results may be due to past or present infection with non-HKU1, NL63, or 229E.</li> </ul>	arly in those who have been in contact with the virus. red to rule out infection in these individuals; s to diagnose or exclude SARS-CoV-2 infection or to inform SARS-CoV-2 coronavirus strains, such as coronavirus